J. Bauch

发表

Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.

K. Glaser, S. Davidsen, V. Stoll, 2005, Journal of medicinal chemistry.

Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor.

K. Glaser, S. Davidsen, V. Stoll, 2007, Journal of medicinal chemistry.

Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study

J. Segreti, S. Rosenberg, H. Sham, 2004, Cancer Chemotherapy and Pharmacology.

Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.

V. Stoll, Eric F. Johnson, X. Liu, 2006, Bioorganic & medicinal chemistry letters.

A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.

Wang Shen, Mary K Joseph, Saul H Rosenberg, 2006, Cancer research.

Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo.

A. Petros, S. Fesik, S. Ng, 2006, Journal of medicinal chemistry.

Antitumor Activity of Orally Bioavailable Farnesyltransferase Inhibitor, ABT-100, Is Mediated by Antiproliferative, Proapoptotic, and Antiangiogenic Effects in Xenograft Models

Haiying Zhang, N. Lin, H. Sham, 2005, Clinical Cancer Research.

Potent inhibitors of protein farnesyltransferase: heteroarenes as cysteine replacements.

S. Ng, P. Kovar, S. Rosenberg, 1999, Bioorganic & medicinal chemistry letters.

3,5-Bis(trifluoromethyl)pyrazoles: a novel class of NFAT transcription factor regulator.

Xiaoping Zhou, U. Warrior, C. Wegner, 2000, Journal of medicinal chemistry.

Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.

S. Davidsen, M. Michaelides, P. Tapang, 2001, Bioorganic & Medicinal Chemistry Letters.

Endothelin receptor antagonist has limited access to the fetal compartment during chronic maternal administration late in pregnancy.

L. Thaete, Sylvia Synowiec, B. Dayton, 2012, Life sciences.

Evaluation of the oral antimitotic agent (ABT-751) in dogs with lymphoma.

C. Khanna, A. Krivoshik, E. McKeegan, 2012, Journal of veterinary internal medicine.

Use of the H3 receptor antagonist radioligand [3H]‐A‐349821 to reveal in vivo receptor occupancy of cognition enhancing H3 receptor antagonists

K. Browman, J. Brioni, J. Bauch, 2009, British journal of pharmacology.

ABT-888 , an OrallyActive Poly ( ADP-Ribose ) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in PreclinicalTumorModels

Eric F. Johnson, T. DeWeese, X. Liu, 2007 .

Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.

Saul H Rosenberg, Xiaohong Song, Milan Bruncko, 2008, Journal of medicinal chemistry.

Pyridone-containing farnesyltransferase inhibitors: synthesis and biological evaluation.

Haiying Zhang, S. Rosenberg, N. Lin, 2003, Bioorganic & medicinal chemistry letters.

New antimitotic agents with activity in multi-drug-resistant cell lines and in vivo efficacy in murine tumor models.

S. Rosenberg, S. L. Gwaltney, R. B. Credo, 2001, Journal of medicinal chemistry.

ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

Eric F. Johnson, T. DeWeese, X. Liu, 2007, Clinical Cancer Research.

Tumour‐selective antivascular effects of the novel anti‐mitotic compound A‐318315: An in vivo rat regional haemodynamic study

J. Segreti, S. Rosenberg, H. Sham, 2010, Clinical and experimental pharmacology & physiology.

Aryl tetrahydropyridine inhibitors of farnesyltransferase: bioavailable analogues with improved cellular potency.

V. Stoll, S. Muchmore, S. Ng, 2003, Bioorganic & medicinal chemistry letters.

A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation.

M. Bergo, S. Young, C. Coffinier, 2006, The Journal of clinical investigation.

Synthesis of 1H-pyridin-2-one derivatives as potent and selective farnesyltransferase inhibitors.

R. Henry, Haiying Zhang, S. Rosenberg, 2004, Bioorganic & medicinal chemistry letters.

Design, synthesis, and biological activity of 4-[(4-cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles as potent and selective farnesyltransferase inhibitors.

V. Stoll, Y. Tong, Haiying Zhang, 2004, Journal of medicinal chemistry.

Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates

V. Giranda, T. Horton, B. Dayton, 2008, Cancer Chemotherapy and Pharmacology.

Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models

C. Tse, S. Fesik, S. Rosenberg, 2008, Clinical Cancer Research.

ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo

C. Tse, S. Fesik, S. Chemburkar, 2008, Molecular Cancer Therapeutics.

Conditioning of drug-induced immunomodulation in human volunteers: a European collaborative study.

C. Kirschbaum, J. Hennig, A. Buske-Kirschbaum, 1992, The British journal of clinical psychology.

Second-generation peptidomimetic inhibitors of protein farnesyltransferase demonstrating improved cellular potency and significant in vivo efficacy.

S. Ng, P. Kovar, S. Rosenberg, 1999, Journal of medicinal chemistry.

Plasma and cerebrospinal fluid pharmacokinetics of intravenously administered ABT-751 in non-human primates

Steve Y. Cho, F. Balis, K. Marsh, 2007, Cancer Chemotherapy and Pharmacology.

Zotarolimus, a Novel Sirolimus Analogue With Potent Anti-proliferative Activity on Coronary Smooth Muscle Cells and Reduced Potential for Systemic Immunosuppression

Yung-wu Chen, J. Trevillyan, G. Carter, 2007, Journal of cardiovascular pharmacology.

Discovery of potent imidazole and cyanophenyl containing farnesyltransferase inhibitors with improved oral bioavailability.

V. Stoll, Y. Tong, Haiying Zhang, 2003, Bioorganic & medicinal chemistry letters.

ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo

S. Fesik, S. Chemburkar, S. Rosenberg, 2008, Molecular Cancer Therapeutics.